Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Icotinib with Chemotherapy in EGFR-Mutated NSCLC
NCT03983811Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
01
Overview
Randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Chemotherapy+Icotinib with Chemotherapy+Placebo (2 arms). Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03983811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983811.